Predictive value of plasma exosomal deleted in lymphocytic leukemia 1 level in immunotherapy response of epidermal growth factor receptor/anaplastic lymphoma kinase wild type advanced non-small cell lung cancer patients
LIU Qiuxia JI Longfei HU Yanqin PAN Nannan QIANG Xinhua LI Yong
Department of Laboratory, the First People’s Hospital of Huzhou, Zhejiang Province, Huzhou 313000, China
Abstract：Objective To investigate the clinical significance of plasma exosomal deleted in lymphocytic leukemia 1 (exo- DLEU1) in predicting immunotherapy response of epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild type advanced non-small cell lung cancer (NSCLC) patients. Methods The blood samples of 91 patients with EGFR/ALK wild type advanced NSCLC who received immunotherapy in the First People’s Hospital of Huzhou, Zhejiang Province from June 2017 to February 2019 were collected and divided into response group (53 cases) and non-response group (38 cases) according to the response after immunotherapy. Plasma exosomes were extracted from the two groups before treatment, and exoDLEU1 expression was detected by real-time fluorescent quantitative PCR. The influencing factors of immunotherapy response in EGFR/ALK wild type advanced NSCLC patients were analyzed by logistic regression. Receiver operator characteristic (ROC) curve was plotted to evaluate the predictive value of plasma exoDLEU1 level in immunotherapy response. Results Under transmission electron microscopy, the vesicles had circular or elliptical membranes with diameters ranging from 30 to 150 nm, and the original concentration was 6.6×1010 particles /ml. Flow cytometry and Western blot showed that the extracts contained exosome markers CD63, CD9, CD81, and heat shock protein 70. Real-time fluorescence quantitative PCR results showed that the plasma exoDLEU1 level in the response group before treatment was lower than that in the non-response group, and the difference was statistically significant (P＜0.05). Analysis of influencing factors showed that plasma exoDLEU1 expression level was an independent influencing factor for immunotherapy non-response in EGFR/ALK wild type advanced NSCLC patients (OR=6.119, 95%CI: 2.768-13.526, P＜0.05). ROC curve analysis showed that plasma exoDLEU1 expression level predicted immunotherapy response of EGFR/ALK wild type advanced NSCLC patients with an area under the curve of 0.900 (P＜0.05). Conclusion The plasma exoDLEU1 level of EGFR/ALK wild type advanced NSCLC patients before immunotherapy can be used as an indicator to predict their treatment response, and help to screen out patients who are more likely to benefit from immunotherapy in the clinic.
柳秋霞 嵇龙飞 胡燕勤 潘楠楠 强鑫华 李勇. 血浆外泌体淋巴细胞白血病缺失基因1水平对表皮生长因子受体/间变性淋巴瘤激酶野生型进展期非小细胞肺癌患者免疫治疗反应的预测价值[J]. 中国医药导报, 2023, 20(32): 28-32.
LIU Qiuxia JI Longfei HU Yanqin PAN Nannan QIANG Xinhua LI Yong. Predictive value of plasma exosomal deleted in lymphocytic leukemia 1 level in immunotherapy response of epidermal growth factor receptor/anaplastic lymphoma kinase wild type advanced non-small cell lung cancer patients. 中国医药导报, 2023, 20(32): 28-32.
[1] Lim SM，Hong MH，Kim HR. Immunotherapy for Non-small Cell Lung Cancer：Current Landscape and Future Perspectives [J]. Immune Netw，2020，20（1）：e10-e23. [2] Onoi K，Chihara Y，Uchino J，et al. Immune Checkpoint Inhibitors for Lung Cancer Treatment：A Review [J]. J Clin Med，2020，9（5）：1362-1376. [3] Pandey P，Khan F，Qari HA，et al. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1，PD-L1 and CTLA-4 [J]. Pharmaceuticals，2022，15（3）：335-349. [4] Pollack MH，Betof A，Dearden H，et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events（irAEs）during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma [J]. Ann Oncol，2018，29（1）：250-255. [5] 陈婷，蒋晓东.外泌体在非小细胞肺癌中的研究进展[J].现代肿瘤医学，2022，30（11）：2073-2076. [6] 赵林林，王艳亭，李小江，等.外泌体非编码RNA在非小细胞肺癌获得性耐药中的研究进展[J].中国肿瘤临床，2022，49（1）：42-46. [7] Paskeh MDA，Entezari M，Mirzaei S，et al. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling [J]. J Hematol Oncol，2022，15（1）：83-121. [8] 陈宇.长链非编码RNA对肺癌发生、发展、诊断及预后评估作用的研究进展[J].国际检验医学杂志，2022，43（22）：2793-2797. [9] Song C，Zhang J，Zhao Z，et al. DLEU1：A Functional Long Noncoding RNA in Tumorigenesis [J]. Curr Pharm Des，2020，26（15）：1742-1748. [10] Detterbeck FC，Boffa DJ，Kim AW，et al. The Eighth Edition Lung Cancer Stage Classification [J]. Chest，2017，151（1）：193-203. [11] Wood DE，Kazerooni EA，Baum SL，et al. Lung Cancer Screening，Version 3.2018，NCCN Clinical Practice Guidelines in Oncology [J]. J Natl Compr Canc Netw，2018，16（4）：412-441. [12] Shimamura SS，Shukuya T，Asao T，et al. Survival past five years with advanced，EGFR-mutated or ALK-rearranged non-small cell lung cancer——is there a“tail plateau”in the survival curve of these patients？[J]. BMC Cancer，2022，22（1）：323-332. [13] Eisenhauer EA，Therasse P，Bogaerts J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline（version 1.1）[J]. Eur J Cancer，2009，45（2）：228-247. [14] Hodi FS，Ballinger M，Lyons B，et al. Immune-Modified Response Evaluation Criteria In Solid Tumors （imRECIST）：Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy [J]. J Clin Oncol，2018，36（9）：850-858. [15] 杜凤华，梅晓冬.循环生物标志物在预测非小细胞肺癌免疫治疗反应的研究进展[J].临床肺科杂志，2021，26（3）：443-446. [16] Peng XX，Yu R，Wu X，et al. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer [J]. J Immunother Cancer，2020，8（1）：e000376. [17] Sun KD，Ni YJ，Qin H，et al. LncRNA DLEU1 facilitates the progression of oral squamous cell carcinoma by miR- 126-5p/GAB1 axis [J]. Kaohsiung J Med Sci，2022，38（10）： 950-959. [18] Zhang S，Guan Y，Liu X，et al. Long non-coding RNA DLEU1 exerts an oncogenic function in non-small cell lung cancer [J]. Biomed Pharmacother，2019，109：985-990. [19] Lv QL，Wang LC，Li DC，et al. Knockdown lncRNA DLEU1 inhibits gliomas progression and promotes temozolomide chemosensitivity by regulating autophagy [J]. Front Pharmacol，2020，11：560543-560557. [20] Ma HN，Chen HJ，Liu JQ，et al. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2 [J]. Cell Death Dis，2022，13（7）：625-633. [21] 张杰，刘索，甘毅，等.非小细胞肺癌中lncRNA DLEU1的表达对肿瘤细胞转移的影响[J].中国肿瘤临床，2018， 45（23）：1181-1186. [22] Lv X，Liu L，Li P，et al. Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients [J]. Reprod Sci，2022，29（3）：800-815. [23] 顾睿，刘敏，林苹，等.m6A修饰相关lncRNA与宫颈癌的预后不良及免疫治疗的相关性分析[J].四川大学学报（医学版），2022，53（4）：626-636. [24] Zhang Y，Fan H，Zou C，et al. Screening seven hub genes associated with prognosis and immune infiltration in glioblastoma [J]. Front Genet，2022，13：924802-924813. [25] Sun J，Zhang Z，Bao S，et al. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer [J]. J Immunother Cancer，2020，8（1）：e000110.
2023, Vol. 20 
京公网安备 11010502046598号